Ann: Understanding Alzheimer's Symposium, page-25

First 25 Last

Share
Profile

Follow
PapaLaz

584 Posts.

28

22/10/15

17:18

Post #: 16232720
Share

Originally posted by pop2 ↑

From today's Australian.
This comment was interesting - "Results should be evident in as little as four weeks"

Actinogen (ACW) 6.3c
While our attention was elsewhere, Alzheimer’s disease quietly overtook cancer as the nation’s second-biggest cause of death, behind only heart failure.
According to Actinogen chief Bill Ketelbey this reflects the medical profession’s success in treating cancer and the fact we are living longer.
Still, that’s no solace for the sufferers of the malady that has proved an elephant’s graveyard for failed new drugs.
Actinogen is changing tack with its compound Xanamem, by targeting the hormone cortisol which rises and falls with stress levels. “If your cortisol goes up and stays up over time, it becomes problematic,’ Ketelbey told the Australian Microcap Investment Conference yesterday. “But reverse that and cognition improves.’’
A precursor material administered to 2576 forgetful rodents showed memory improvement in 28 days. The tricky bit is overcoming the body’s natural resistance that makes it hard to deliver material from the blood to the brain. But Actinogen’s phase-one trial involving 88 patients suggests this hurdle may have been overcome.
The next step is a phase-two study of 200 patients with mild Alzheimer’s, funded by $11m of equity raised in May. Results should be evident in as little as four weeks. “It looks like we might be able to treat the symptom as well as modify the disease,’’ Ketelbey says.
Should the trial flop, Ketelbey argues Xanamem also has potential applications for Parkinson’s disease, schizophrenia and depression, diabetes and post traumatic stress disorder.
Actinogen shares surged an “anomalous” 36 per cent to 15c in day and just as quickly down again — just before the raising executed at 9.5c a share. Actinogen is valued at $30m. Compare that to the Nasdaq-listed Avanir Pharma, picked off by Otsuka Pharma for $US3.5 billion after phase-two results. Spec buy.

Expand

Great find thanks for posting.

ACW Price at posting: 6.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Making money: How many microcaps should be in an investor's portfolio?

Finance school vs reality: What they don't teach you about the stock market

There are more pages in this discussion • 1 more message in this thread...

First 25 Last

Add ACW (ASX) to my watchlist

(20min delay)
Last 2.6¢		Change 0.000(0.00%)		Mkt cap ! $76.57M

Open	High	Low	Value	Volume
2.5¢	2.6¢	2.5¢	$128.5K	4.961M

Buyers (Bids)

No.	Vol.	Price($)
31	8008551	2.5¢

Sellers (Offers)

Price($)	Vol.	No.
2.6¢	2036470	1

View Market Depth

No.	Vol.	Price($)
31	8008551	0.025
18	4434414	0.024
9	2495777	0.023
11	3327351	0.022
8	837738	0.021

Price($)	Vol.	No.
0.026	2036470	1
0.027	2037932	6
0.028	1211783	7
0.029	969187	8
0.030	717700	6

Last trade - 15.06pm 28/10/2024 (20 minute delay)

ACW (ASX) Chart

Ann: Understanding Alzheimer's Symposium, page-25

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Making money: How many microcaps should be in an investor's portfolio?

Finance school vs reality: What they don't teach you about the stock market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Understanding Alzheimer's Symposium, page-25

Top Stories

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Making money: How many microcaps should be in an investor's portfolio?

Finance school vs reality: What they don't teach you about the stock market

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News